**Supplementary Figure S7**



**Supplementary Figure S7. MET regulates STING expression by UPF1.**

**A-B,** Blots of the indicated proteins in H1993 and H820 cells transduced with control shRNA or STING shRNA and treated with 2,3 c-GAMP (5 μg/ml) for 6 h and tivantinib (200 nM) for 48 h.

**C,** qPCR analysis of STING mRNA levels in H1993 and H820 cells transduced with con shRNA, MET shRNA or MET shRNA reconstituted with WT MET or MET kinase dead (KD) plasmid. (Unpaired, two-tailed Student's t-tests; *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$).

**D,** *STING* mRNA stability in H1993 and H820 cells treated with DMSO, MET inhibitor tivantinib (200 nM) or HGF (50 ng/ml). Cells were pre-treated with DMSO, MET inhibitor for 24hours or HGF for 12hours before adding actinomycin D (ACTD) (5ug/ml). (Unpaired, two-tailed Student's t-tests; *$p < 0.05$, **$p < 0.01$, ns not significant).

**E,** qPCR analysis of *STING* mRNA after transfection with indicated shRNAs in H1993 cells. (Unpaired, two-tailed Student's t-tests; **$p < 0.01$, ns not significant).

**F,** qPCR analysis of STING mRNA level in H1993 cells transfected with control shRNA or UPF1 shRNA. Cells were treated with or without HGF (left panel); or transfected with vector or MET cDNA (right panel). (Unpaired, two-tailed Student's t-tests; *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, ns not significant).

**G,** qPCR analysis STING mRNA stability of H1993 and H820 cells 48 h after transfection with indicated shRNA and HGF (50 ng/ml) treatment. Cells were pre-treated with PBS or HGF for 12 hours before adding actinomycin D (ACTD, 5 ug/ml). (Mean ± SEM from biological triplicates. Unpaired, two-tailed Student's t-tests; *$p < 0.05$, **$p < 0.01$).